REAL-WORLD OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND SUBSTANCE ABUSE DISORDERS TREATED WITH GLECAPREVIR/PIBRENTASVIR FOR 8 WEEKS: A POOLED ANALYSIS OF MULTINATIONAL POST-MARKETING OBSERVATIONAL STUDIES

被引：0
|
作者：
Rizzardini, Giuliano [1 ]
Gschwantler, Michael [2 ]
Bourgeois, Stefan [3 ]
Mullhaupt, Beat [4 ,5 ]
Mazur, Wlodzimierz [6 ]
Bondin, Mark [7 ]
Zhang, Zhenzhen [7 ]
Marra, Fiona [8 ]
Veitsman, Ella [9 ]
Mimidis, Konstantinos [10 ]
Marques, Nuno [11 ]
Foucher, Juliette [12 ]
机构：
[1] Asst Fatebenefratelli Sacco, Div Infect Dis 1, Milan, Italy
[2] Wilhelminenspital Stadt Wien, Dept Internal Med 4, Vienna, Austria
[3] Stuivenberg Zna, Antwerp, Belgium
[4] Univ Hosp Zurich, Dept Gastroenterol & Hepatol, Zurich, Switzerland
[5] Univ Zurich, Zurich, Switzerland
[6] Med Univ Silesia, Clin Dept Infect Dis, Katowice, Poland
[7] Abbvie Inc, N Chicago, IL USA
[8] Univ Liverpool, Hepatol Drug Interact Grp, Liverpool, Merseyside, England
[9] Rambam Hlth Care Campus, Liver Unit, Haifa, Israel
[10] Democritus Univ Thrace, Sch Med, Dept Internal Med 1, Xanthi, Greece
[11] Hosp Garcia Orta Epe, Infect Dis Serv, Almada, Portugal
[12] Hop Haut Leveque, Pessac, France
来源：
HEPATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
929
引用
收藏
页码：568A / 569A
页数：2
相关论文
共 47 条
  • [21] Comparison of 8-versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting
    Lu, Yung-Hsin
    Lu, Chung-Kuang
    Chen, Chun-Hsien
    Hsieh, Yung-Yu
    Tung, Shui-Yi
    Chen, Yi-Hsing
    Yen, Chih-Wei
    Tung, Wei-Lin
    Chang, Kao-Chi
    Chen, Wei-Ming
    Lu, Sheng-Nan
    Hung, Chao-Hung
    Chang, Te-Sheng
    PLOS ONE, 2022, 17 (08):
  • [22] Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)
    Cornberg, Markus
    Stoehr, Albrecht
    Naumann, Uwe
    Teuber, Gerlinde
    Klinker, Hartwig
    Lutz, Thomas
    Moller, Hjoerdis
    Hidde, Dennis
    Lohmann, Kristina
    Simon, Karl-Georg
    VIRUSES-BASEL, 2022, 14 (07):
  • [23] Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study
    Ogawa, Eiichi
    Furusyo, Norihiro
    Nakamuta, Makoto
    Nomura, Hideyuki
    Satoh, Takeaki
    Takahashi, Kazuhiro
    Koyanagi, Toshimasa
    Kajiwara, Eiji
    Dohmen, Kazufumi
    Kawano, Akira
    Ooho, Aritsune
    Azuma, Koichi
    Kato, Masaki
    Shimoda, Shinji
    Hayashi, Jun
    HEPATOLOGY RESEARCH, 2019, 49 (06) : 617 - 626
  • [24] Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies
    Zuckerman, Eli
    Gutierrez, Julio
    Ustianowski, Andrew
    Naggie, Susanna
    Caruntu, Florin Alexandru
    Ravendhran, Natarajan
    Sigal, Samuel
    Barrett, Lisa
    Cohen, Stanley
    Crown, Eric
    Dylla, Doug
    Fredrick, Linda
    Wang, Stanley
    Porcalla, Ariel
    Mensa, Federico
    Bruno, Savino
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E251 - E251
  • [25] EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR TREATMENT FOR 8 WEEKS IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS: ANALYSIS OF DATA POOLED FROM PHASE 2 AND 3 STUDIES
    Gutierrez, Julio
    Zuckerman, Eli
    Ustianowski, Andrew
    Naggie, Susanna
    Caruntu, Florin
    Ravendhran, Natarajan
    Sigal, Samuel
    Barrett, Lisa
    Cohen, Stanley M.
    Crown, Eric
    Dylla, Doug
    Fredrick, Linda
    Wang, Stanley
    Porcalla, Ariel R.
    Mensa, Federico
    Bruno, Savino
    GASTROENTEROLOGY, 2019, 156 (06) : S1218 - S1218
  • [26] Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
    Krishnan, Preethi
    Pilot-Matias, Tami
    Schnell, Grega
    Tripathi, Rakesh
    Ng, Teresa I.
    Reisch, Thomas
    Beyer, Jill
    Dekhtyar, Tatyana
    Irvin, Michelle
    Xie, Wangang
    Larsen, Lois
    Mensa, Federico J.
    Collins, Christine
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (10)
  • [27] Effectiveness of 8 weeks of glecaprevir/pibrentasvir in treatment-naive hepatitis C patients with liver cirrhosis: results from the real-world Spanish Hepa-C registry
    Turnes, Juan
    Hernandez-Guerra, Manuel
    Souto Rodriguez, Raquel
    Fernandez, Inmaculada
    Carrion, Jose A.
    de Cuenca Moron, Beatriz
    Manuel Pascasio, Juan
    Moreno Planas, Jose Maria
    Moreno, Jose Juan
    Bellot, Pau
    Delgado, Manuel
    Salmeron, Javier
    Marino, Zoe
    Rosales Zabal, Jose Miguel
    Garcia-Samaniego Rey, Francisco Javier
    Morillas, Rosa
    Diago, Moises
    Crespo, Javier
    Gonzalez Santiago, Jesus
    Mateos Munoz, Beatriz
    Torras, Xavier
    Badia-Aranda, Esther
    Bonet, Lucia
    Menendez, Fernando
    Bernal Monterde, Vanesa
    Marquez Rodriguez, Paqui
    Arenas, Juan
    Prieto, Martin
    Perez Cachafeiro, Santiago
    JOURNAL OF HEPATOLOGY, 2020, 73 : S346 - S347
  • [28] Real-world health care resource utilization and quality of life with G/P treatment: A pooled analysis from post-marketing observational studies
    Aghemo, Alessio
    Bourgeois, Stefan
    Gschwantler, Michael
    Sanchez, Yuri
    Larsen, Lois
    Bondin, Mark
    Magenta, Lorenzo
    Asselah, Tarik
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E207 - E207
  • [29] FROM CLINICAL TRIALS TO REAL-WORLD EVIDENCE: SIMILAR VIROLOGIC CURE RATES AND SAFETY OUTCOMES FOLLOWING TREATMENT WITH GLECAPREVIR/PIBRENTASVIR AMONG PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND RECENT DRUG USE
    Aghemo, Alessio
    Negro, Francesco
    Gschwantler, Michael
    Asselah, Tarik
    Bondin, Mark I.
    Crown, Eric D.
    Mancine, Miki
    Zhang, Zhenzhen
    Flisiak, Robert
    Grebely, Jason
    Brau, Norbert
    Sterling, Richard K.
    HEPATOLOGY, 2019, 70 : 932A - 933A
  • [30] Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in hepatitis C virus genotype 1-and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries
    Ferenci, Peter
    Bourgeois, Stefan
    Buggisch, Peter
    Norris, Suzanne
    Curescu, Manuela
    Larrey, Dominique
    Marra, Fiona
    Kleine, Henning
    Dorr, Patrick
    Charafeddine, Mariem
    Crown, Eric
    Bondin, Mark
    Back, David
    Flisiak, Robert
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (06) : 685 - 696
12345